Tag Archives: Thomson Reuters

Study Points to Dramatic Drop In R&D Expenditure

By Guest Blogger | Published: June 29, 2011
Pharma expenditure on R&D has dropped to an estimated $68 billion, according to Thomson Reuters’ 2011 Pharmaceutical R&D Factbook. The three-year low demonstrates the receding trends of drug success, the amount of drugs entering Phase I and II trials and the number of new molecular entities (NMEs) launched in the global market.
Posted in Global, Guest Blog, R&D | Also tagged , , , | 1 Comment

Two 'Most Promising' New Drugs Face Setbacks in US

By Ben Comer | Published: March 22, 2011
Two of the drugs named “most promising” in Thomson Reuters’ recent quarterly report hit snags in the US, despite European approval. Those two products – AstraZeneca’s Brilique (Brilinta in the US), a blood thinner, and Pharming’s Ruconest (Rhucin in the US) – were held up during FDA’s review process. Brilique (ticagrelor), AstraZeneca’s leading pipeline drug, was [...]
Posted in FDA, Global, R&D, Regulatory, Sales | Also tagged , , , , | Leave a comment